Genmab A/S (Germany) Performance
| GE9 Stock | EUR 270.50 4.40 1.60% |
On a scale of 0 to 100, Genmab A/S holds a performance score of 8. The company retains a Market Volatility (i.e., Beta) of 0.0912, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Genmab A/S's returns are expected to increase less than the market. However, during the bear market, the loss of holding Genmab A/S is expected to be smaller as well. Please check Genmab A/S's information ratio, total risk alpha, treynor ratio, as well as the relationship between the jensen alpha and sortino ratio , to make a quick decision on whether Genmab A/S's current trending patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Genmab AS are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Genmab A/S reported solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Can Genmab A S Depositary Receipt stock withstand economic slowdown - July 2025 Analyst Calls Daily Stock Trend Watchlist - newser.com | 11/12/2025 |
2 | Genmab Valuation in Focus After Recent Share Price Pullback - Yahoo Finance | 11/18/2025 |
3 | Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami - Yahoo Finance UK | 11/24/2025 |
4 | Merus Acquired by Genmab, Leadership Changes Announced - TipRanks | 12/12/2025 |
5 | Genmab Drops Acasunlimab to Refocus Investment on Late-Stage Cancer Pipeline - TipRanks | 12/29/2025 |
6 | Genmab Valuation Check As Anthropic AI Alliance Supports Late Stage Pipeline Progress - simplywall.st | 01/15/2026 |
7 | Genmab s Future Potential Underappreciated by Market - Yahoo Finance UK | 01/21/2026 |
8 | GENMAB AS Stands Out as a Peter Lynch-Style GARP Investment - Chartmill | 01/29/2026 |
Genmab |
Genmab A/S Relative Risk vs. Return Landscape
If you would invest 24,520 in Genmab AS on November 4, 2025 and sell it today you would earn a total of 2,970 from holding Genmab AS or generate 12.11% return on investment over 90 days. Genmab AS is currently producing 0.2124% returns and takes up 2.1019% volatility of returns over 90 trading days. Put another way, 18% of traded stocks are less volatile than Genmab, and 96% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Genmab A/S Target Price Odds to finish over Current Price
The tendency of Genmab Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 270.50 | 90 days | 270.50 | about 44.38 |
Based on a normal probability distribution, the odds of Genmab A/S to move above the current price in 90 days from now is about 44.38 (This Genmab AS probability density function shows the probability of Genmab Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon Genmab A/S has a beta of 0.0912. This usually indicates as returns on the market go up, Genmab A/S average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Genmab AS will be expected to be much smaller as well. Additionally Genmab AS has an alpha of 0.1171, implying that it can generate a 0.12 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Genmab A/S Price Density |
| Price |
Predictive Modules for Genmab A/S
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Genmab A/S. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Genmab A/S Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Genmab A/S is not an exception. The market had few large corrections towards the Genmab A/S's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Genmab AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Genmab A/S within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.12 | |
β | Beta against Dow Jones | 0.09 | |
σ | Overall volatility | 13.45 | |
Ir | Information ratio | 0.04 |
Genmab A/S Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Genmab A/S for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Genmab A/S can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Genmab A/S is unlikely to experience financial distress in the next 2 years | |
| Latest headline from news.google.com: GENMAB AS Stands Out as a Peter Lynch-Style GARP Investment - Chartmill |
Genmab A/S Fundamentals Growth
Genmab Stock prices reflect investors' perceptions of the future prospects and financial health of Genmab A/S, and Genmab A/S fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genmab Stock performance.
| Return On Equity | 0.29 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.41 % | ||||
| Operating Margin | 0.45 % | ||||
| Current Valuation | 13.51 B | ||||
| Shares Outstanding | 61.49 M | ||||
| Price To Earning | 45.93 X | ||||
| Price To Sales | 4.38 X | ||||
| Revenue | 3.85 B | ||||
| Gross Profit | 3.63 B | ||||
| EBITDA | 1.47 B | ||||
| Net Income | 4.35 B | ||||
| Cash And Equivalents | 921.63 M | ||||
| Cash Per Share | 14.99 X | ||||
| Debt To Equity | 2.40 % | ||||
| Current Ratio | 17.30 X | ||||
| Book Value Per Share | 77.99 X | ||||
| Cash Flow From Operations | 2.23 B | ||||
| Earnings Per Share | 4.86 X | ||||
| Market Capitalization | 16.84 B | ||||
| Retained Earnings | 14.97 B |
About Genmab A/S Performance
By analyzing Genmab A/S's fundamental ratios, stakeholders can gain valuable insights into Genmab A/S's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Genmab A/S has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genmab A/S has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 26.42 | 25.10 | |
| Return On Tangible Assets | 0.23 | 0.24 | |
| Return On Capital Employed | 0.15 | 0.16 | |
| Return On Assets | 0.15 | 0.16 | |
| Return On Equity | 0.19 | 0.20 |
Things to note about Genmab A/S performance evaluation
Checking the ongoing alerts about Genmab A/S for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genmab A/S help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genmab A/S is unlikely to experience financial distress in the next 2 years | |
| Latest headline from news.google.com: GENMAB AS Stands Out as a Peter Lynch-Style GARP Investment - Chartmill |
- Analyzing Genmab A/S's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genmab A/S's stock is overvalued or undervalued compared to its peers.
- Examining Genmab A/S's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genmab A/S's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genmab A/S's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genmab A/S's stock. These opinions can provide insight into Genmab A/S's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Genmab Stock analysis
When running Genmab A/S's price analysis, check to measure Genmab A/S's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab A/S is operating at the current time. Most of Genmab A/S's value examination focuses on studying past and present price action to predict the probability of Genmab A/S's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab A/S's price. Additionally, you may evaluate how the addition of Genmab A/S to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |